<DOC>
	<DOCNO>NCT01920113</DOCNO>
	<brief_summary>Adequate , safe sedation essential Endoscopic submucosal dissection . Dexmedetomidine potent selective a2-adrenoceptor agonist use sedative analgesic effect , limited use alone . The investigator design study compare effect safety two sedative , dexmedetomidine propofol Endoscopic Submucosal Dissection ( ESD ) , sufficient analgesia-remifentanil administer throughout procedure .</brief_summary>
	<brief_title>A Comparison Efficacy Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil Propofol-remifentanil</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Age â‰¥20 American Society Anaesthesiologists ( ASA ) physical status classification I~III Early gastric cancer patient schedule Endoscopic submucosal dissection Age &lt; 20 American Society Anaesthesiologists ( ASA ) physical status classification IV endorgan disease ( i.e . heart failure , respiratory failure , hepatic failure , renal failure ) know drug allergy history drug abuse psychological disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Endoscopic submucosal dissection</keyword>
	<keyword>propofol</keyword>
	<keyword>remifentanil</keyword>
	<keyword>dexmedetomidine</keyword>
	<keyword>efficacy</keyword>
	<keyword>safeness</keyword>
</DOC>